Serina Therapeutics completed sentinel dosing in a Phase 1b trial of SER-252, a subcutaneous apomorphine formulation for advanced Parkinson's disease, with safety approval to proceed ahead of original timeline. The candidate targets motor symptom control while reducing the logistical burden of current infusion-dependent treatments.
Key Points
- Safety Monitoring Committee cleared dose escalation after initial 72-hour safety review
- Trial completion now expected ahead of Q3 2026 original guidance
- Subcutaneous delivery designed to replace frequent intravenous infusion regimens
Longevity Analysis
Parkinson's disease management depends critically on sustained dopaminergic signaling and consistent motor control. Current infusion-based apomorphine therapy requires frequent clinic visits and carries adherence barriers that undermine long-term symptom stability. A subcutaneous formulation that maintains therapeutic exposure with reduced treatment frequency addresses both the neurological and practical dimensions of disease management—improving not just symptom burden but the consistency of treatment delivery that determines functional trajectory in advanced disease. This approach also reduces oxidative stress from repetitive needle puncture and infection risk, supporting the regenerative capacity of affected neural tissue.
Original published by LT Wire.